BACKGROUND AND OBJECTIVES: A meeting of a Canadian group with significant experience and knowledge in HIV management, consisting of five physicians, a pharmacist and an AIDS researcher, was convened. Their goal was to develop guidance for Canadian HIV-treating physicians on the appropriate use of raltegravir (MK-0518, Isentress(R), Merck Frosst Canada Inc) in HIV-infected adults. METHODS: Evidence from the published literature and conference presentations, as well as expert opinions of the group members, was considered and evaluated to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, as well as from five other physicians and scientists across Canada with expertise in HIV treatment and antiretroviral drug resistance, and experience in the use of raltegravir. The final recommendations represent the core group's consensus agreement once all feedback was considered. RESULTS/ CONCLUSIONS: Recommendations were developed to guide physicians in the optimal use of raltegravir. The issues considered included raltegravir's role in overall treatment strategy, efficacy, durability of effect, rate of viral load reduction, resistance, safety/toxicity, pharmacokinetics and drug interactions.
BACKGROUND AND OBJECTIVES: A meeting of a Canadian group with significant experience and knowledge in HIV management, consisting of five physicians, a pharmacist and an AIDS researcher, was convened. Their goal was to develop guidance for Canadian HIV-treating physicians on the appropriate use of raltegravir (MK-0518, Isentress(R), Merck Frosst Canada Inc) in HIV-infected adults. METHODS: Evidence from the published literature and conference presentations, as well as expert opinions of the group members, was considered and evaluated to develop the recommendations. Feedback on the draft recommendations was obtained from this core group, as well as from five other physicians and scientists across Canada with expertise in HIV treatment and antiretroviral drug resistance, and experience in the use of raltegravir. The final recommendations represent the core group's consensus agreement once all feedback was considered. RESULTS/ CONCLUSIONS: Recommendations were developed to guide physicians in the optimal use of raltegravir. The issues considered included raltegravir's role in overall treatment strategy, efficacy, durability of effect, rate of viral load reduction, resistance, safety/toxicity, pharmacokinetics and drug interactions.
Authors: Charles B Hicks; Pedro Cahn; David A Cooper; Sharon L Walmsley; Christine Katlama; Bonaventura Clotet; Adriano Lazzarin; Margaret A Johnson; Dietmar Neubacher; Douglas Mayers; Hernan Valdez Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: M Iwamoto; L A Wenning; A S Petry; M Laethem; M De Smet; J T Kost; S A Merschman; K M Strohmaier; S Ramael; K C Lasseter; J A Stone; K M Gottesdiener; J A Wagner Journal: Clin Pharmacol Ther Date: 2007-08-22 Impact factor: 6.875
Authors: Jacques Reynes; Keikawus Arastéh; Bonaventura Clotet; Calvin Cohen; David A Cooper; Jean-François Delfraissy; Joseph J Eron; Keith Henry; Christine Katlama; Daniel R Kuritzkes; Jacob P Lalezari; Joep Lange; Adriano Lazzarin; Julio S G Montaner; Mark Nelson; Mary O' Hearn; Hans-Jürgen Stellbrink; Benoit Trottier; Sharon L Walmsley; Neil E Buss; Ralph Demasi; Jain Chung; Lucille Donatacci; Denise Guimaraes; Lucy Rowell; Adeline Valentine; Martin Wilkinson; Miklos P Salgo Journal: AIDS Patient Care STDS Date: 2007-08 Impact factor: 5.078
Authors: Larissa A Wenning; Evan J Friedman; James T Kost; Sheila A Breidinger; Jon E Stek; Kenneth C Lasseter; Keith M Gottesdiener; Joshua Chen; Hedy Teppler; John A Wagner; Julie A Stone; Marian Iwamoto Journal: Antimicrob Agents Chemother Date: 2008-07-14 Impact factor: 5.191
Authors: Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Lucinda R Gilde; Hong Wan; Michael D Miller; Larissa A Wenning; Hedy Teppler Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: Marian Iwamoto; Larissa A Wenning; Goutam C Mistry; Amelia S Petry; Sarah Y Liou; Kaylan Ghosh; Sheila Breidinger; Neal Azrolan; Maria J Gutierrez; William E Bridson; Julie A Stone; Keith M Gottesdiener; John A Wagner Journal: Clin Infect Dis Date: 2008-07-01 Impact factor: 9.079
Authors: Alessandro Cozzi-Lepri; Andrew N Phillips; Bonaventura Clotet; Amanda Mocroft; Lidia Ruiz; Ole Kirk; Adriano Lazzarin; Alicja Wiercinska-Drapalo; Anders Karlsson; Jens D Lundgren Journal: AIDS Date: 2008-10-18 Impact factor: 4.177